Evidence map›Paper›PMID 42256325›Full record

ArticleIJU case reports2026

Belzutifan for Metastatic TFE3-Rearranged Renal Cell Carcinoma With Pulmonary Metastases: A Case Report.

Kazutaka Nakamura, Akihiro Kumono, Yuki Kobari, Atsuko Seki, Takayuki Nakayama, Hironori Fukuda, Kazuhiko Yoshida, Junpei Iizuka, Yoji Nagashima, Toshio Takagi

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in IJU case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Kazutaka NakamuraDepartment of Urology Tokyo Women's Medical University Shinjuku-ku Tokyo Japan.ORCID https://orcid.org/0009-0005-2461-0860
Akihiro KumonoDepartment of Urology Tokyo Women's Medical University Shinjuku-ku Tokyo Japan.
Yuki KobariDepartment of Urology Tokyo Women's Medical University Shinjuku-ku Tokyo Japan.
Atsuko SekiDepartment of Surgical Pathology Tokyo Women's Medical University Shinjuku-ku Tokyo Japan.
Takayuki NakayamaDepartment of Urology Tokyo Women's Medical University Shinjuku-ku Tokyo Japan.
Hironori FukudaDepartment of Urology Tokyo Women's Medical University Shinjuku-ku Tokyo Japan.
Kazuhiko YoshidaDepartment of Urology Tokyo Women's Medical University Shinjuku-ku Tokyo Japan.
Junpei IizukaDepartment of Urology Tokyo Women's Medical University Shinjuku-ku Tokyo Japan.
Yoji NagashimaDepartment of Surgical Pathology Tokyo Women's Medical University Shinjuku-ku Tokyo Japan.ORCID https://orcid.org/0000-0002-6536-648X
Toshio TakagiDepartment of Urology Tokyo Women's Medical University Shinjuku-ku Tokyo Japan.ORCID https://orcid.org/0000-0003-1775-0943

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Belzutifan is effective in patients with previously treated advanced clear cell renal cell carcinoma. However, evidence for its use in non-clear cell renal cell carcinoma remains limited. Case Presentation: A 33-year-old Japanese woman underwent total nephrectomy for a 10-cm renal tumor with lung metastases. The histological and immunohistochemical results were consistent with Conclusion: Belzutifan led to radiographic improvement in pulmonary metastases and symptoms, while other lesions remained stable. This suggests its potential therapeutic use in

Indexed as

hypoxia‐inducible factor inhibitorsneoplasm metastasisnephrectomyrenal cell carcinomatranscription Factor TFE3

Identifiers

PMID42256325
PMCPMC13239923

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.